{
  "ticker": "EYPT",
  "company_name": "EyePoint, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06683742",
      "title": "A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Wet Age Related Macular Degeneration, wAMD",
      "start_date": "2024-11-27",
      "completion_date": "2027-10",
      "enrollment": 0,
      "sponsor": "EyePoint Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05191706",
      "title": "Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract",
      "status": "RECRUITING",
      "phase": "PHASE4",
      "condition": "Cataract",
      "start_date": "2022-01-04",
      "completion_date": "2026-02",
      "enrollment": 0,
      "sponsor": "EyePoint Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04747197",
      "title": "First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Wet Age-related Macular Degeneration",
      "start_date": "2021-01-20",
      "completion_date": "2022-05-11",
      "enrollment": 0,
      "sponsor": "EyePoint Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02746991",
      "title": "Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Posterior Uveitis, Intermediate Uveitis, Panuveitis",
      "start_date": "2015-06-02",
      "completion_date": "2019-10-04",
      "enrollment": 0,
      "sponsor": "EyePoint Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04511650",
      "title": "Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "COVID-19, Acute Respiratory Distress Syndrome (ARDS)",
      "start_date": "2020-10-21",
      "completion_date": "2021-02-26",
      "enrollment": 0,
      "sponsor": "EyePoint Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04781335",
      "title": "\"A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu\u2122) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation\"",
      "status": "COMPLETED",
      "phase": "PHASE4",
      "condition": "Cataract",
      "start_date": "2020-02-20",
      "completion_date": "2022-12-22",
      "enrollment": 0,
      "sponsor": "The Eye Institute of West Florida"
    },
    {
      "nct_id": "NCT05550350",
      "title": "A Study to Evaluate the Efficacy and Safety of DEXYCU\u00ae for the Treatment of Ocular Pain Associated With Cataract Surgery",
      "status": "WITHDRAWN",
      "phase": "PHASE3",
      "condition": "Cataract",
      "start_date": "2022-09",
      "completion_date": "2023-09",
      "enrollment": 0,
      "sponsor": "EyePoint Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05070728",
      "title": "Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Uveitis, Uveitis, Posterior, Uveitis, Intermediate",
      "start_date": "2021-10-13",
      "completion_date": "2023-04-12",
      "enrollment": 0,
      "sponsor": "EyePoint Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04405245",
      "title": "Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Ocular Hypertension, Primary Open Angle Glaucoma",
      "start_date": "2020-06-06",
      "completion_date": "2020-11-05",
      "enrollment": 0,
      "sponsor": "EyePoint Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06099184",
      "title": "Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Diabetic Macular Edema",
      "start_date": "2024-01-15",
      "completion_date": "2024-10-24",
      "enrollment": 0,
      "sponsor": "EyePoint Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 18,
    "by_phase": {
      "PHASE3": 8,
      "PHASE4": 2,
      "PHASE1": 1,
      "PHASE2": 6,
      "": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 2,
      "RECRUITING": 1,
      "COMPLETED": 11,
      "TERMINATED": 2,
      "WITHDRAWN": 2
    },
    "active_trials": 3,
    "completed_trials": 11,
    "conditions": [
      "COVID-19, Acute Respiratory Distress Syndrome (ARDS)",
      "Cataract",
      "Diabetic Macular Edema",
      "Non-Infectious Uveitis",
      "Nonproliferative Diabetic Retinopathy",
      "Ocular Hypertension, Primary Open Angle Glaucoma",
      "Posterior Uveitis, Intermediate Uveitis, Panuveitis",
      "Uveitis, Uveitis, Posterior, Uveitis, Intermediate",
      "Wet Age Related Macular Degeneration, wAMD",
      "Wet Age-related Macular Degeneration"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:20.842868",
    "search_query": "EyePoint, Inc.",
    "url": "https://clinicaltrials.gov/search?term=EyePoint,+Inc."
  }
}